<DOC>
	<DOCNO>NCT02195011</DOCNO>
	<brief_summary>The purpose study determine safety regorafenib , antiangiogenic drug , combine radioembolization use SIR-Spheres® microspheres treatment colorectal cancer ( CRC ) spread liver .</brief_summary>
	<brief_title>Safety Study Regorafenib SIR-Spheres® Microspheres Radioembolization Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases</brief_title>
	<detailed_description>Recent target therapy treatment strategy show promise colorectal cancer ; however , elimination disease remain challenge spread liver . Radioembolization use SIR-Spheres® microspheres ( SIR-Spheres ) treat liver-only liver-dominant metastatic colorectal cancer ( mCRC ) successful refractory set . In open-label study compare safety two treatment cohort radioembolization administer use device SIR-Spheres microspheres ( 90Y resin microspheres ) combination regorafenib patient mCRC liver metastasis . The two treatment cohort evaluate safety , overall response rate ( ORR ) , progression-free survival ( PFS ) , overall survival ( OS ) .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>1 . Histologically confirm metastatic adenocarcinoma colon rectum . 2 . Patients previously treat candidate fluorouracil , oxaliplatin , irinotecan , Kras wildtype , anti EGFR therapy . 3 . Considered appropriate candidate regorafenib therapy . 4 . Measurable disease evaluable disease measure Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 . 5 . Measurable computed tomography ( CT ) scan evidence liver metastases treatable surgical resection local ablation curative intent time study entry . 6 . ECOG Performance Status score 01 . 7 . Adequate hematologic , renal kidney function . 8 . Male patient female partner childbearing potential woman female patient childbearing potential require use two form acceptable contraception , include one barrier method , participation study 30 day follow last dose . 9 . Life expectancy ≥ 3 month . 10 . Ability understand nature study give write informed consent 1 . Most recent chemotherapy ≤14 day ≥Grade 1 chemotherapyrelated side effect , exception alopecia . 2 . Use study drug ≤21 day 5 halflives ( whichever short ) prior initiation study treatment . For study drug 5 halflives ≤21 day , minimum 10 day termination study drug administration study treatment require . 3 . Wide field radiotherapy ( include therapeutic radioisotope strontium89 administer ≤28 day limit field radiation palliation ≤7 day prior start study drug recover side effect therapy . 4 . Previous radiation deliver upper abdomen . 5 . Major surgical procedure ≤28 day begin study drug , minor surgical procedure ≤7 day . No wait require follow portacath placement . 6 . Previously untreated brain metastasis . Patients receive radiation surgery brain metastasis eligible therapy complete least 2 week previously evidence central nervous system disease progression , mild neurologic symptom , requirement chronic corticosteroid therapy . 7 . Leptomeningeal metastasis spinal cord compression due disease . 8 . Pregnant lactating . 9 . Evidence ascites , cirrhosis , portal hypertension , thrombosis determine clinical radiologic assessment . 10 . History abdominal fistula gastrointestinal perforation ≤6 month prior begin study treatment . 11 . Serious nonhealing wound , active ulcer , untreated bone fracture . 12 . Presence active gastrointestinal disease condition interfere significantly absorption , distribution , metabolism , excretion oral therapy ( e.g . ulcerative disease , uncontrolled nausea , vomit , diarrhea Grade ≥2 , malabsorption syndrome ) . 13 . Any following cardiac disease currently within last 6 month : Unstable angina pectoris Congestive heart failure ( NYHA ≥ Grade 2 ) Conduction abnormality control pacemaker medication Significant ventricular supraventricular arrhythmia ( patient chronic ratecontrolled atrial fibrillation absence cardiac abnormality eligible ) Valvular disease significant compromise cardiac function 14 . Inadequately control hypertension ( i.e. , systolic blood pressure [ SBP ] &gt; 180 mmHg diastolic blood pressure ( DBP ) &gt; 100 mmHg ) ( patient value level must blood pressure ( BP ) control medication prior start treatment ) . 15 . Serious active infection time treatment , another serious underlie medical condition would impair ability patient receive protocol treatment . 16 . Known diagnosis human immunodeficiency virus , hepatitis B , hepatitis C. 17 . Presence active cancer , history treatment invasive cancer ≤5 year . Patients Stage I cancer receive definitive local treatment consider unlikely recur eligible . All patient previously treat situ carcinoma ( i.e. , noninvasive ) eligible , patient history nonmelanoma skin cancer . 18 . Use strong CYP34A inducer inhibitor . 19 . The herbal medication St. John 's wort , kava , ephedra ( huang ) , gingko biloba , dehydroepiandrosterone ( DHEA ) , yohimbe , saw palmetto , ginseng allow study treatment . Patients stop use herbal medication 7 day prior first dose study drug . 20 . Psychological , familial , sociological , geographical condition permit compliance protocol . 21 . Inability unwillingness comply study and/or followup procedure outline protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Regorafenib</keyword>
	<keyword>90Y</keyword>
	<keyword>Radioembolization</keyword>
	<keyword>SIR-Spheres Microspheres</keyword>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Liver Metastases</keyword>
	<keyword>SIRT</keyword>
	<keyword>Refractory</keyword>
</DOC>